RWE Where RCTs Fall Short: Optimizing Frontline Treatment of HR+/HER2- Metastatic Breast Cancer

7 episodes

0.75 program credits

51m

Details

Episodes

Documents

Presenters

Comments

Overview
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Target Audience
This activity has been designed to meet the educational needs of the interprofessional team, including medical oncologists, nurses, and pharmacists, as well as other clinicians involved in the management of patients with HR+/HER2-metastatic breast cancer (MBC).
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Critically evaluate components of RWE publications to distinguish high-quality from low-quality sources of information
- Evaluate RWE of CDK4/6 inhibitors in HR+/HER2- MBC as it relates to clinical trial evidence
- Apply RWE to make treatment decisions for patients regarding the choice of CDK4/6 inhibitors in HR+/HER2- MBC
- Increase clinician awareness of the patient's perspective on the existence and utility of RWE as it applies to shared decision-making conversations
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Faculty Disclosure of Commercial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.

The following faculty have disclosed:

Adam Brufsky, MD, PhD, faculty for this educational event, is a contracted researcher for AstraZeneca, Pfizer, Novartis, Lilly, Genentech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi, Puma, and Myriad.

Christopher M. Gallagher, MD, faculty for this educational event, is a contracted researcher for AstraZeneca, Lilly Oncology, and Daiichi Sankyo; and receives consulting fees from AstraZeneca, Lilly Oncology, and Daiichi Sankyo.
Planners and Managers Disclosure List
The following planners/reviewers/managers have disclosed:

Megan Reimann, PharmD, BCOP, planner for this educational event, has no relevant financial relationships with ineligible companies.

William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

Total CME, LLC., planners, and managers have no relevant commercial relationships to disclose.

All the relevant financial relationships for these individuals have been mitigated.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use their clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go, you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Provider(s)/Educational Partner(s)
Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.
Commercial Support
This activity is supported by an independent educational grant from Pfizer Inc.
Instructions for Completion
During the period 12/8/2023 through 12/8/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:
1. Read the learning objectives and faculty disclosures.
2. Answer a pre-program question.
3. View the program.
4. Complete the post-test with a score of 100%.
5. Complete activity evaluation.
6. Apply for credit and either bank your credits or print your certificate.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/08/2023
Expiration Date: 12/08/2024